Daily Newsletter

20 September 2024

Daily Newsletter

20 September 2024

AngioDynamics initiates thrombectomy system trial across Europe

The company’s RECOVER-AV trial is intended to further the adoption of its AlphaVac F1885 system in the European market.

Ross Law September 20 2024

US medtech AngioDynamics has initiated a trial of its AlphaVac F1885 thrombectomy system for treating patients with acute pulmonary embolism (PE).

The company’s AlphaVac system, which received CE marking in Europe and 510(k) clearance from the US Food and Drug Administration (FDA) earlier this year, uses a funnel cannula design for the non-surgical and manual aspiration of blood clots in PE patients.

Following the initiation of a similar trial in the US last year, the RECOVER-AV study will enrol patients with confirmed acute, intermediate-risk PE in up to 20 European hospitals.

The study’s primary endpoint is a reduction in the right ventricular/left ventricular (RV/LV) ratio from baseline to 48 hours post-procedure. The study also includes a primary safety endpoint for assessing the incidence of major adverse events (MAEs), such as device-related death or major bleeding, within seven days.

Previous research has estimated that around 435,000 PE events occur in the six largest European nations annually while other research indicates that compared to the US, PE incidence is higher for patients admitted to emergency departments in Europe, and with higher acuity and worse patient outcomes overall.

AngioDynamics senior vice-president and general manager of endovascular therapies Laura Piccinini commented: “With our clinical partners, we are demonstrating our continued commitment to generating robust clinical evidence across the world, with this being the first international study we have sponsored highlighting our commitment as a global leader to treat more patients and advance care.”

According to GlobalData, the global manual thrombectomy device market was valued at around $157m in 2023 and is forecast to reach a valuation of around $174m by 2033.

Elsewhere in thrombectomy, FlowPhysix (formerly Expanse ICE) recently partnered with 3comma Medical for the international distribution of its aspiration catheter, the FlowRunner Aspiration System.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close